A study in the Journal of Clinical Psychopharmacology found that overall use of long-acting injectable antipsychotics for the treatment of schizoaffective disorder was low, and adherence to antipsychotics was suboptimal among these patients in the real-world setting.
Researchers from Janssen Scientific Affairs and Novosys Health evaluated real-world treatment patterns and adherence to antipsychotics among commercially insured U.S. patients with schizoaffective disorder aged ≥18 years; patient data was obtained from the Clinformatics Data Mart database.
Study patients were divided into either incident (n=1,961) or prevalent (n=752) schizoaffective disorder. The use of psychiatric treatments and adherence to antipsychotics was assessed during a 12-month follow-up period after index diagnosis of schizoaffective disorder.
Antipsychotic medications were used by 74.8% of patients in the overall population during the follow-up period. The most commonly prescribed oral antipsychotic was risperidone (23.9%), followed by quetiapine (21.4%) and aripiprazole (20.4%). The use of any long-acting injectable antipsychotics during the follow-up period was <3%.
Study authors further reported that 49% and 38% of the overall study population had medication possession ratios and proportion of days covered for antipsychotics ≥80%, respectively. Findings indicate suboptimal adherence among patients with schizoaffective disorder and a generally low use of long-acting injectable antipsychotics.
For more information visit journals.lww.com.